After a great deal of confusion and what turned out to be an error on my part I wish to let you know that the NICE (The U.K.’s National Institute for Health and Care Excellence) Guidance I shared on the blog on January 28, 2014 (http://advancedprostatecancer.net/?p=4360 ) about enzalutamide (Xtandi) was not accurate. In my [...]
The first line of treatment for advanced prostate cancer is Androgen (male hormone) Deprivation Therapy or ADT. Once the PSA progresses (climbs) while still on ADT and with testosterone levels
Recently men with advanced prostate cancer have found that their insurance companies have been dictating what drugs they can get instead of their doctor making the best decision for them. At Malecare we have seen that when a man with metastatic castrate resistant prostate cancer (mCRPC) has finished taking chemotherapy they have been steered by [...]
The treatment of advanced prostate cancer, and in particular castrate resistant prostate cancer (CRPC), has changed greatly over the last 4 years. Treatment options have expanded and now offer multiple treatment possibilities that did not exist 4 years ago. With the addition of all these new options, so comes the addition of significant economic costs, [...]
Since it FDA approval in 2004, docetaxel (a taxane based chemotherapy) has been the standard first-line chemotherapy for men with metastatic prostate cancer (mCRPC). Other than the trial of Provenge all the successful phase III trials conducted in mCRPC focused on men experiencing cancer progression after first-line docetaxel chemotherapy. The implication is that improving the [...]
According to researchers at Weill Cornell Medical College in the Sept. 15 issue of the journal Cancer Research, taxne-based chemotherapy drugs are not well understood as they may be more powerful than many have believed. Generally, it is believed that taxane chemotherapy (paclitaxel, docetaxel and cabazitaxel) just stop a cancer cell from dividing -- but [...]
At the recent European Multidisciplinary Cancer Congress in Stockholm, Dr Chris Parker from The Royal Marsden Hospital presented results of the phase 3 ALSYMPCA trial that showed both delayed time to first skeletal-related event (SRE) AND an overall survival (OS) benefit for those men with advanced prostate cancer taking radium-223 (Alpharadin). The real significance of [...]
Things are looking up for our European readers. It must be frustrating for people outside of the United States to read this blog and learn about the many advances we now have in the US which are not available to them. The good news is that Sanofi has just launched Jevtana (cabazitaxel) in the UK [...]
There is good reason for guarded optimism among men with advanced prostate cancer. Over the last 2 years we have seen some significant movement with the development of new drugs and treatments for men with advanced prostate cancer. All of these drugs have demonstrated a survival advantage in their clinical trials. Each of the agents [...]
Today’s big news is about a media release made yesterday by Centocor Ortho Biotech with the official and final results of the Phase III clinical trial of abiraterone acetate (Zytiga™) plus prednisone vs. prednisone alone in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already received at least one course of a docetaxel based [...]
